biostudies-literatureUnknown208(1)Thiruvengadam SKGenentech, Inc.GenentechA high unmet need for novel, safe and effective therapies exists among older patients with non-Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B-cell NHL (B-NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B-NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, oBritish journal of haematology149-158https://www.ebi.ac.uk/biostudies/studies/S-EPMC12819098biostudies-literatureMosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.PMC12819098Zhou MMei MWu MThiruvengadam SKYin SZuo XPopplewell LLNikolaenko LMun YBudde LEHerrera AFWei MCfalseMosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.A high unmet need for novel, safe and effective therapies exists among older patients with non-Hodgkin lymphoma (NHL). We report safety and efficacy of mosunetuzumab in a subgroup analysis of a phase I/II study, which examined the prognostic impact of age in 218 patients with relapsed/refractory (R/R) B-cell NHL (B-NHL; ≥65 years, n = 102; <65 years, n = 116) from the phase I expansion cohort (NCT02500407) and further evaluated 90 patients with R/R follicular lymphoma (FL; ≥65 years, n = 30; <65 years, n = 60) from the pivotal cohort. The most common adverse event (AE) was cytokine release syndrome, occurring less frequently in older versus younger (33.3% vs. 44.8%) patients with B-NHL. Serious AEs were similar in older versus younger patients (45.1% vs. 46.6%). For patients with R/R FL, o2026-01-01T00:00:00Z2026 Jan2026-06-06T19:29:44.765Z2026-06-04T03:10:51.136ZS-EPMC128190984125480610.1111/bjh.70212